Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.
Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.
Relay Therapeutics director Douglas S. Ingram received a grant of stock options covering 32,947 shares of common stock. The options carry an exercise price of $14.09 per share and were granted as a compensation-related award, not an open-market purchase or sale.
According to the terms, the award vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders following that grant date. After this grant, Ingram holds options for 32,947 underlying shares.
Relay Therapeutics, Inc. director Lonnel Coats received a new stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted on June 9, 2026 as compensation, not an open-market purchase.
The option vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, and expires on June 8, 2036. Following this grant, Coats holds stock options for 32,947 underlying shares directly.
Relay Therapeutics director Mark Murcko received a new stock option award. The grant covers 32,947 shares of common stock at an exercise price of $14.09 per share and expires on June 8, 2036.
According to the terms, the option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date. After this award, Murcko holds options for 32,947 shares directly.
Relay Therapeutics reported results from its 2026 annual stockholder meeting and a key charter change. Stockholders approved an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, and the company filed a Certificate of Second Amendment in Delaware to implement this change.
Two Class III directors, Douglas S. Ingram and Claire Mazumdar, Ph.D., were elected for terms ending at the 2029 annual meeting. Stockholders also approved, on a non-binding basis, the compensation of named executive officers and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Relay Therapeutics, Inc. entered into an underwriting agreement with Jefferies and TD Securities for an underwritten public offering of 22,916,667 shares of common stock at $12.00 per share. Underwriters received a 30-day option for up to 3,437,500 additional shares, which was exercised in full on May 21, 2026.
The company expects net proceeds of approximately $296.8 million after underwriting discounts and expenses. The offering, made off an effective Form S-3ASR shelf using a May 20, 2026 prospectus supplement, is expected to close on May 22, 2026, subject to customary conditions.
Relay Therapeutics is offering 22,916,667 shares of common stock at $12.00 per share. The prospectus supplement dated May 20, 2026 states estimated net proceeds of approximately $258.0 million (about $296.8 million if the underwriters exercise their 30-day option in full for an additional 3,437,500 shares). The offering assumes 189,209,453 shares outstanding as of March 31, 2026. Net tangible book value per share would be $4.24 after the offering, producing immediate dilution of $7.76 per new share. Proceeds are planned to fund research and clinical development, working capital, capital expenditures and general corporate purposes.
Relay Therapeutics is offering $175,000,000 of common stock. The preliminary prospectus supplement dated May 19, 2026, states the company is offering shares of its common stock for aggregate proceeds of $175,000,000, with underwriters holding a 30-day option to purchase up to an additional $26,250,000 of shares.
All information about shares outstanding is based on 189,209,453 shares outstanding as of March 31, 2026. The prospectus supplement cites intended use of net proceeds to fund research and clinical development, working capital, capital expenditures and other general corporate purposes.
Relay Therapeutics is offering $175,000,000 of common stock. The preliminary prospectus supplement dated May 19, 2026, states the company is offering shares of its common stock for aggregate proceeds of $175,000,000, with underwriters holding a 30-day option to purchase up to an additional $26,250,000 of shares.
All information about shares outstanding is based on 189,209,453 shares outstanding as of March 31, 2026. The prospectus supplement cites intended use of net proceeds to fund research and clinical development, working capital, capital expenditures and other general corporate purposes.
Relay Therapeutics reported initial Phase 2 ReInspire data for zovegalisib in PIK3CA‑driven vascular anomalies. As of the April 15, 2026 data cut-off, 32 adults and adolescents were enrolled across 100mg, 300mg and 400mg twice‑daily dose cohorts, with all patients remaining on treatment.
Among 20 response‑evaluable patients, 60% achieved a volumetric response, defined as at least a 20% MRI‑measured reduction in target lesion volume, and 95% experienced some lesion shrinkage. At week 12, investigator‑ and patient‑reported outcome scores showed clinical improvement in 89% and 79% of patients, respectively, while pain scores improved for 71% of pain symptoms.
Safety at 100mg and 300mg twice daily appeared manageable: 23% of patients had dose reductions, median dose intensity exceeded 99%, and only 2 patients (9%) experienced Grade 3 or higher treatment‑related adverse events, with no discontinuations due to adverse events. The 400mg twice‑daily dose showed a less favorable safety profile and has been deprioritized, while expansion cohorts are open at 300mg twice daily and 400mg once daily.
Relay Therapeutics reported initial Phase 2 ReInspire data for zovegalisib in PIK3CA‑driven vascular anomalies. As of the April 15, 2026 data cut-off, 32 adults and adolescents were enrolled across 100mg, 300mg and 400mg twice‑daily dose cohorts, with all patients remaining on treatment.
Among 20 response‑evaluable patients, 60% achieved a volumetric response, defined as at least a 20% MRI‑measured reduction in target lesion volume, and 95% experienced some lesion shrinkage. At week 12, investigator‑ and patient‑reported outcome scores showed clinical improvement in 89% and 79% of patients, respectively, while pain scores improved for 71% of pain symptoms.
Safety at 100mg and 300mg twice daily appeared manageable: 23% of patients had dose reductions, median dose intensity exceeded 99%, and only 2 patients (9%) experienced Grade 3 or higher treatment‑related adverse events, with no discontinuations due to adverse events. The 400mg twice‑daily dose showed a less favorable safety profile and has been deprioritized, while expansion cohorts are open at 300mg twice daily and 400mg once daily.
Relay Therapeutics, Inc. Schedule 13G/A (Amendment No. 2) reports that Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen each report 0% beneficial ownership of Relay Therapeutics common stock as of the close of business on March 31, 2026. The filing lists the reporting persons' principal business address in Stamford, Connecticut and identifies the class by CUSIP 75943R102.
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo sold 17,717 shares of common stock in an open-market transaction at a weighted average price of $12.86 per share. The trade was carried out under a Rule 10b5-1 trading plan adopted on October 30, 2025.
After this sale, he directly holds 195,178 shares, which include 9,807 shares underlying restricted stock units. The transaction was executed in multiple trades at prices ranging from $12.67 to $13.42 per share.